# US 12,109,232 B2 · Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,232 B2
- Document ID: US12109232B2
- Status: Granted
- Kind: B2
- Application number: 17/328,865
- Filed: 2021-05-24
- Published: 2021-12-30
- Granted: 2024-10-08
- Earliest claimed: 2013-02-15
- Assignees: KORTUC Inc.
- Applicants: Kortuc Inc.
- Inventors: Yasuhiro Ogawa; Shiho Tokuhiro; Hideki Oda; Norikazu Yokota; Ryo Akima
- Web page: https://patentgrep.com/patent/US12109232B2

## CPC

- A61K 33/40: Peroxides
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a radiation sensitizer or anti-cancer chemotherapy sensitizer that prevents the decomposition of hydrogen peroxide for a longer period of time, and that maintains its effect. The radiation sensitizer or anti-cancer chemotherapy sensitizer according to the present invention is characterized by using hydrogen peroxide together with a hydrogel containing a crosslinked gelatin gel.

## Claims

### Claim 1

A sensitizer comprising a combination of: (a) hydrogen peroxide at a concentration of 0.5 to 3.5 w/v % and (b) a hydrogel comprising a crosslinked gelatin gel prepared from a gelatin having an isoelectric point of 4.5 to 5, wherein the crosslinked gelatin gel is in a particulate form, the hydrogel is at a concentration of 0.5 to 10 w/v %, and the sensitizer is in an intratumoral injection form.

### Claim 2 (depends on 1)

The sensitizer according to claim 1, wherein the crosslinked gelatin gel has a water content of 92 to 99.7%.

### Claim 3 (depends on 2)

The sensitizer according to claim 2, which, in form of a final formulation, is administered in an amount of 0.1 to 10 mg on a dry weight basis of the crosslinked gelatin gel, per 200 mm3 of the tumor volume.

### Claim 4 (depends on 3)

The sensitizer according to claim 3, which, in form of a final formulation, is administered in an amount of 0.1 to 1 mg on a dry weight basis of the crosslinked gelatin gel, per 200 mm3 of the tumor volume.

### Claim 5 (depends on 1)

The sensitizer according to claim 1, wherein the hydrogen peroxide is at a concentration of 0.5 to 3.0 w/v % and the hydrogel is at a concentration of 1.67 to 5 w/v %.

### Claim 6 (depends on 1)

The sensitizer according to claim 1, wherein the hydrogen peroxide is at a concentration of 0.5 to 2.0 w/v % and the hydrogel is at a concentration of 1.67 to 5 w/v %.

### Claim 7 (depends on 1)

The sensitizer according to claim 1, wherein the hydrogen peroxide is at a concentration of 0.5 to 2 w/v % and the hydrogel is at a concentration of 1.67 w/v %.